Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
9.38
-0.12
(-1.32%)
At close: 1:28:41 PM GMT
Key Executives
Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Timothy Paul McCarthy XIV, FCCA, M.B.A., MBA | Executive Chairman | 138.36k | -- | 1956 |
| Dr. Simon Julian Ward | CEO & Director | 134.54k | -- | 1967 |
| Ms. Laura Jane Brogden | Chief Financial Officer | -- | -- | 1980 |
| Ms. Suzanne Carole Brocks | Company Secretary & Head of Communications | -- | -- | 1971 |
Incanthera plc
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 7
Description
Incanthera plc, a dermatology and oncology therapeutics company, focuses on the dermatological formulation and delivery technologies for various indications. It develops skincare products under the Skin + CELL brand name. The company was founded in 2010 and is headquartered in Manchester, the United Kingdom.
Corporate Governance
Incanthera plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
December 18, 2024 at 7:00 AM UTC
Incanthera plc Earnings Date
Recent Events
Recent Events Information Not Available